New results are in for the ASCOT Trial (Australasian Covid-19 Trial), another study in Spiral’s manifest of platform trials. This platform trial was set up to evaluate 3 different treatment approaches for effectiveness against COVID-19. Each of these approaches is called a 'domain'. The findings from the anticoagulation domain have recently been published in the New England Journal of Medicine Evidence.

As clinical trials in the world grow and develop, so too do the opportunities for Spiral to make a difference with our savvy platform software. 

We speak to Professor Steven Tong about the SNAP Trial, his experience working with the team at Spiral, and the application and impact of our Spinnaker software in his study.

At Spiral, we’re always working hard to better meet the needs of our clients and partners. As our product evolves so too does our team. Meet Anna Williams, the newest full-time member of the Spiral whānau (family). Our office manager and data coordinator.  

Over ten thousand participants from right across the UK have now taken part in the NIHR-funded and supported PANORAMIC trial - the world’s largest study into new antiviral treatments against COVID-19 in community, ambulatory care.

REMAP-CAP, the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia, has recently hit a significant date in its trial history, celebrating two years since the first Covid-19 ICU patient was randomised into the trial.

Spiral is pleased to announce our involvement in another incredibly exciting trial, aimed at producing effective Covid-19 treatments for critical care patients.

REMAP-CAP an application in Spiral’s study manifest, has recently been used in a collaborative clinical trial that focused on identifying effective treatments for critically ill Covid-19 patients.